Skip to main content

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

  • The original article was published in Journal of Hematology & Oncology 2019 12:94

Correction to: J Hematol Oncol (2019) 12:94

https://doi.org/10.1186/s13045-019-0786-6

Drs Meghdad Abdollahpour-Alitappeh & Majid Lotfinia and their colleagues, Sajad Yaghoubi, Aliyar Pirouzi, Mohammad Hossein Karimi, Tohid Gharibi, Motahare Mahi-Birjand, Shiva Mohammadi, Koushan Sineh Sepehr, Nader Bagheri from Iran have written to the Journal of Hematology & Oncology regarding the article on antibody-drug conjugates (ADC) [1]. They raised the question that moxetumomab pasudotox (MS) is not an ADC. We appreciate their attention to the publication. We wish to make correction and clarification on this question. First of all, they are correct in pointing out that MS is not a conventional ADC which is usually an antibody conjugated to a cytotoxic chemical payload [2]. MS is an antibody conjugated to a cytotoxic bacterial toxin payload, which is commonly referred to as immunotoxin [3]. Considering the scope and topic of the contents we summarized on the clinical use of ADCs for lymphoma and multiple myeloma, we believe it may be better to keep the section in the article, but with the specific correction that MS is not a conventional ADC, rather an antibody-toxin conjugate, an immunotoxin.

References

  1. 1.

    Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94.

    Article  Google Scholar 

  2. 2.

    Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, Johari B, Zali MR, Bagheri N. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628–42.

    CAS  Article  Google Scholar 

  3. 3.

    Hassan R, Alewine C, Pastan I. New life for Immunotoxin Cancer therapy. Clin Cancer Res. 2016;22(5):1055–8.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Delong Liu.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yu, B., Liu, D. Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol 13, 65 (2020). https://doi.org/10.1186/s13045-020-00902-5

Download citation